Talnetant

TargetMol
Product Code: TAR-T7549
Supplier: TargetMol
CodeSizePrice
TAR-T7549-1mg1mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-2mg2mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-5mg5mg£138.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-10mg10mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-1mL1 mL * 10 mM (in DMSO)£187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-25mg25mg£295.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-50mg50mg£484.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7549-100mg100mg£699.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Talnetant is a selective, competitive, brain-penetrant NK3 receptor antagonist with the ability to modulate mesolimbic and mesocortical dopaminergic neurotransmission
CAS:
174636-32-9
Formula:
C25H22N2O2
Molecular Weight:
382.463
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.98
SMILES:
CCC(NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1
Target:
Neurokinin receptor

References

Giuseppe A. M. Giardina,,?, Luca F. Raveglia,?, Mario Grugni,?, et al. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).[J]. Journal of Medicinal Chemistry, 1999, 42(6):1053-1065. Dawson L A , Cato K J , Scott C , et al. In Vitro and In Vivo Characterization of the Non-peptide NK3 Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia[J]. Neuropsychopharmacology, 2008, 33(7):1642-1652.